These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 26728598)
1. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Matalkah F; Martin E; Zhao H; Agazie YM Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. Zhao H; Agazie YM BMC Cancer; 2015 Mar; 15():109. PubMed ID: 25885600 [TBL] [Abstract][Full Text] [Related]
3. Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET. Liu JJ; Li Y; Chen WS; Liang Y; Wang G; Zong M; Kaneko K; Xu R; Karin M; Feng GS J Hepatol; 2018 Jul; 69(1):79-88. PubMed ID: 29505847 [TBL] [Abstract][Full Text] [Related]
8. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Nakachi I; Naoki K; Soejima K; Kawada I; Watanabe H; Yasuda H; Nakayama S; Yoda S; Satomi R; Ikemura S; Terai H; Sato T; Ishizaka A Mol Cancer Res; 2010 Aug; 8(8):1142-51. PubMed ID: 20647329 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade. Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Zhou XD; Agazie YM Cell Death Differ; 2008 Jun; 15(6):988-96. PubMed ID: 18421299 [TBL] [Abstract][Full Text] [Related]
11. JC-010a, a novel selective SHP2 allosteric inhibitor, overcomes RTK/non-RTK-mediated drug resistance in multiple oncogene-addicted cancers. Lu X; Yu R; Li Z; Yang M; Dai J; Liu M Cancer Lett; 2024 Feb; 582():216517. PubMed ID: 38101609 [TBL] [Abstract][Full Text] [Related]
12. SHP2 Potentiates the Oncogenic Activity of β-Catenin to Promote Triple-Negative Breast Cancer. Martin E; Agazie YM Mol Cancer Res; 2021 Nov; 19(11):1946-1956. PubMed ID: 34389690 [TBL] [Abstract][Full Text] [Related]
13. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Phuchareon J; McCormick F; Eisele DW; Tetsu O Proc Natl Acad Sci U S A; 2015 Jul; 112(29):E3855-63. PubMed ID: 26150526 [TBL] [Abstract][Full Text] [Related]
14. Combinatorial inhibition of PTPN12-regulated receptors leads to a broadly effective therapeutic strategy in triple-negative breast cancer. Nair A; Chung HC; Sun T; Tyagi S; Dobrolecki LE; Dominguez-Vidana R; Kurley SJ; Orellana M; Renwick A; Henke DM; Katsonis P; Schmitt E; Chan DW; Li H; Mao S; Petrovic I; Creighton CJ; Gutierrez C; Dubrulle J; Stossi F; Tyner JW; Lichtarge O; Lin CY; Zhang B; Scott KL; Hilsenbeck SG; Sun J; Yu X; Osborne CK; Schiff R; Christensen JG; Shields DJ; Rimawi MF; Ellis MJ; Shaw CA; Lewis MT; Westbrook TF Nat Med; 2018 May; 24(4):505-511. PubMed ID: 29578538 [TBL] [Abstract][Full Text] [Related]
15. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer. Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749 [TBL] [Abstract][Full Text] [Related]
16. BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Herr R; Halbach S; Heizmann M; Busch H; Boerries M; Brummer T Oncogene; 2018 Mar; 37(12):1576-1593. PubMed ID: 29326440 [TBL] [Abstract][Full Text] [Related]
17. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436 [TBL] [Abstract][Full Text] [Related]
18. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. Meyer AS; Miller MA; Gertler FB; Lauffenburger DA Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085 [TBL] [Abstract][Full Text] [Related]
19. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378 [TBL] [Abstract][Full Text] [Related]
20. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Hartman ZR; Schaller MD; Agazie YM Mol Cancer Res; 2013 Jun; 11(6):651-64. PubMed ID: 23512980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]